[Screening for chromosomal abnormalities using nuchal translucency measurement with materal serum biochemistry markers in first trimester].

Objective: To Investigate the performance of prenatal screening for chromosomal abnormalities in first trimester.

Methods: Maternal serum were collected from 2 739 pregnant women between 11 and 14 weeks gestation. Free beta human chorionic gonadotrophin(beta-hCG), pregnancy-associated plasma protein(PAPP-A) from materal serum were measured using time resolved fluorescence immunoassay(TRFIA) and fetal nuchal translucency(NT) thickness were measured using transabdominal or transvaginal ultrasound.